JP2005530515A - アポトーシスの検出方法 - Google Patents

アポトーシスの検出方法 Download PDF

Info

Publication number
JP2005530515A
JP2005530515A JP2004517874A JP2004517874A JP2005530515A JP 2005530515 A JP2005530515 A JP 2005530515A JP 2004517874 A JP2004517874 A JP 2004517874A JP 2004517874 A JP2004517874 A JP 2004517874A JP 2005530515 A JP2005530515 A JP 2005530515A
Authority
JP
Japan
Prior art keywords
nucleolin
parp
antibody
detecting
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004517874A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005530515A5 (cg-RX-API-DMAC7.html
Inventor
ポーラ ジェイ ベイツ
インチャン ミ
Original Assignee
ユニヴァーシティー オヴ ルイスヴィル リサーチ ファウンデイション インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニヴァーシティー オヴ ルイスヴィル リサーチ ファウンデイション インコーポレイテッド filed Critical ユニヴァーシティー オヴ ルイスヴィル リサーチ ファウンデイション インコーポレイテッド
Publication of JP2005530515A publication Critical patent/JP2005530515A/ja
Publication of JP2005530515A5 publication Critical patent/JP2005530515A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/25—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving enzymes not classifiable in groups C12Q1/26 - C12Q1/66
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91091—Glycosyltransferases (2.4)
    • G01N2333/91142—Pentosyltransferases (2.4.2)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Saccharide Compounds (AREA)
JP2004517874A 2002-06-26 2003-06-26 アポトーシスの検出方法 Pending JP2005530515A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39214302P 2002-06-26 2002-06-26
PCT/US2003/020167 WO2004003554A1 (en) 2002-06-26 2003-06-26 A method for the detection of apoptosis

Publications (2)

Publication Number Publication Date
JP2005530515A true JP2005530515A (ja) 2005-10-13
JP2005530515A5 JP2005530515A5 (cg-RX-API-DMAC7.html) 2006-08-10

Family

ID=30000819

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004517874A Pending JP2005530515A (ja) 2002-06-26 2003-06-26 アポトーシスの検出方法

Country Status (8)

Country Link
US (2) US20040132049A1 (cg-RX-API-DMAC7.html)
EP (1) EP1516186B1 (cg-RX-API-DMAC7.html)
JP (1) JP2005530515A (cg-RX-API-DMAC7.html)
AT (1) ATE458196T1 (cg-RX-API-DMAC7.html)
AU (2) AU2003248724A1 (cg-RX-API-DMAC7.html)
CA (1) CA2489520A1 (cg-RX-API-DMAC7.html)
DE (1) DE60331310D1 (cg-RX-API-DMAC7.html)
WO (1) WO2004003554A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009162564A (ja) * 2007-12-28 2009-07-23 Hitachi Plant Technologies Ltd アポトーシス検出方法及び装置

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1181304E (pt) * 1999-04-08 2008-01-23 Antisoma Res Ltd Actividade antiproliferativa de oligonucleótidos ricos em g e método de utilização dos mesmos para ligação a nucleolina
US8114850B2 (en) * 1999-04-08 2012-02-14 Advanced Cancer Therapeutics, Llc Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US7960540B2 (en) 1999-04-08 2011-06-14 Advanced Cancer Therapeutics, Llc Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US20110178161A1 (en) * 1999-04-08 2011-07-21 Antisoma Research Limited Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US7541150B2 (en) 2002-04-08 2009-06-02 University Of Louisville Research Foundation, Inc Method for the diagnosis and prognosis of malignant diseases
US7357928B2 (en) * 2002-04-08 2008-04-15 University Of Louisville Research Foundation, Inc. Method for the diagnosis and prognosis of malignant diseases
KR20050114217A (ko) 2003-02-21 2005-12-05 메드벳 싸이언스 피티와이. 리미티드 진단 및 치료 방법
JP5025724B2 (ja) * 2006-04-18 2012-09-12 ウェルスタット バイオロジクス コーポレイション 循環腫瘍性細胞からのタンパク質の検出
US20080187894A1 (en) * 2006-12-14 2008-08-07 Cady Roger K Method and System for Interactive Cognitive Testing
US20090131351A1 (en) * 2007-11-16 2009-05-21 Antisoma Research Limited Methods, compositions, and kits for modulating tumor cell proliferation
WO2009088837A2 (en) * 2007-12-31 2009-07-16 The University Of Louisville Research Foundation, Inc. Methods and products to target, capture and characterize stem cells
US9260517B2 (en) 2009-11-17 2016-02-16 Musc Foundation For Research Development Human monoclonal antibodies to human nucleolin
US20130052647A1 (en) * 2010-02-10 2013-02-28 Marianna Goldrick Methods for fractionating and processing microparticles from biological samples and using them for biomarker discovery
EP2714094B1 (en) 2011-06-02 2016-02-24 The University of Louisville Research Foundation, Inc. Anti-nucleolin agent-conjugated nanoparticles
UA105278C2 (ru) 2012-09-06 2014-04-25 Інститут Біології Клітини Нан України Способ получения каталитически активных антител (абзимов) с сиалидазной активностью
HK1251488A1 (zh) 2015-05-05 2019-02-01 The University Of Louisville Research Foundation, Inc. 作为放射致敏剂以及mri和/或x光造影剂的结合纳米粒子的抗核仁素剂
CN111579538B (zh) * 2020-04-22 2022-12-30 山东第一医科大学(山东省医学科学院) 一种利用凋亡试剂盒检测循环肿瘤细胞的方法
CN117054200B (zh) * 2023-07-21 2024-11-26 伊莱瑞特(武汉)生物技术有限公司 用于流式细胞术分析凋亡细胞的tunel专用固定破膜剂及其制备方法与应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4474892A (en) * 1983-02-16 1984-10-02 Board Of Trustees Of The Leland Stanford Junior University Two-site immunoassays using monoclonal antibodies of different classes or subclasses and test kits for performing same
US5169774A (en) * 1984-02-08 1992-12-08 Cetus Oncology Corporation Monoclonal anti-human breast cancer antibodies
US4671256A (en) * 1984-05-25 1987-06-09 Lemelson Jerome H Medical scanning, monitoring and treatment system and method
US5055459A (en) * 1986-06-30 1991-10-08 Board Of Regents, The University Of Texas Selective elimination of malignant cells from bone marrow by bis (acyloxy) propylphosphoramidates
US4987071A (en) * 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5192660A (en) * 1989-04-24 1993-03-09 The United States Of America As Represented By The Department Of Health And Human Services ELISA methods for the determination of human platelet derived growth factor (PDGF) dimer forms present in human tissues and fluids
US6020145A (en) * 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
AU635008B2 (en) * 1989-12-13 1993-03-11 Genelabs Diagnostics Pte Ltd Analytical apparatus and method for automated blot assay
US6657103B1 (en) * 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5736348A (en) * 1990-11-28 1998-04-07 Fundacao Oswaldo Cruz (Fiocruz) Method for the immunological diagnosis of Chagas' Disease using recombinant antigens
US5691447A (en) * 1995-03-24 1997-11-25 Tanox Biosystems, Inc. GC1q receptor, HIV-1 gp120 region binding thereto, and related peptides and targeting antibodies
US6096532A (en) * 1995-06-07 2000-08-01 Aastrom Biosciences, Inc. Processor apparatus for use in a system for maintaining and growing biological cells
US6048703A (en) * 1996-11-15 2000-04-11 Cephalon, Inc. Methods for detecting cell apoptosis
CA2284084A1 (en) * 1997-03-12 1998-09-17 Institut Pasteur A novel cell surface receptor for hiv retroviruses, therapeutic and diagnostic uses
EP1003856A1 (en) * 1997-06-05 2000-05-31 Board of Regents, The University of Texas System Apaf-1, the ced-4 human homolog, an activator of caspase-3
JP3614866B2 (ja) * 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 人工抗体ポリペプチド
US6339075B1 (en) * 1997-06-30 2002-01-15 The University Of British Columbia Use of dextran and other polysaccharides to improve mucus clearance
WO1999006588A1 (en) * 1997-08-04 1999-02-11 The Burnham Institute A cell-free system of mitochondria-dependent apoptosis, and methods of use thereof
US6325785B1 (en) * 1997-08-14 2001-12-04 Sherwood Services Ag Sputum trap manifold with nested caps
US5925334A (en) * 1997-08-27 1999-07-20 Rubin; Bruce K. Use of surface active agents to promote mucus clearance
US5932475A (en) * 1997-12-12 1999-08-03 Incyte Pharmaceuticals, Inc. Human nucleolin-like protein
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6306404B1 (en) * 1998-07-14 2001-10-23 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid A
EP1116029B1 (en) * 1998-09-24 2007-12-26 Promega Corporation Apoptosis marker antibodies and methods of use
CA2363984A1 (en) * 1999-04-15 2000-10-26 Merck Frosst Canada & Co. Antibodies that recognize app cleaved by caspases and methods of use
US7070924B1 (en) * 1999-11-08 2006-07-04 Eisai Co., Ltd. Method of detecting cell death and detection reagent
US20020028488A1 (en) * 2000-06-19 2002-03-07 Sujay Singh Transgenic avian species for making human and chimeric antibodies
US7541150B2 (en) * 2002-04-08 2009-06-02 University Of Louisville Research Foundation, Inc Method for the diagnosis and prognosis of malignant diseases
US7357928B2 (en) * 2002-04-08 2008-04-15 University Of Louisville Research Foundation, Inc. Method for the diagnosis and prognosis of malignant diseases
US20110011002A1 (en) * 2006-01-17 2011-01-20 Christian Guillemette Semi-removable window frame assembly
KR20120074311A (ko) * 2009-10-21 2012-07-05 헬스 리서치 인코포레이티드 종양 영상화의 증강을 위한 폴리아크릴산 나노입자

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009162564A (ja) * 2007-12-28 2009-07-23 Hitachi Plant Technologies Ltd アポトーシス検出方法及び装置

Also Published As

Publication number Publication date
WO2004003554A1 (en) 2004-01-08
US20040132049A1 (en) 2004-07-08
EP1516186B1 (en) 2010-02-17
ATE458196T1 (de) 2010-03-15
EP1516186A4 (en) 2006-11-22
AU2010202118A1 (en) 2010-06-17
US20110065121A1 (en) 2011-03-17
DE60331310D1 (de) 2010-04-01
EP1516186A1 (en) 2005-03-23
CA2489520A1 (en) 2004-01-08
AU2003248724A1 (en) 2004-01-19

Similar Documents

Publication Publication Date Title
US20110065121A1 (en) Method for the detection of apoptosis
JP5712198B2 (ja) 悪性疾病の診断および予知方法
AU2004279837B2 (en) A method for the treatment of malignant diseases by inhibiting nucleolin
JP3485186B2 (ja) サイクリン複合体の転位およびそれに関連する使用
JP6075881B2 (ja) 乳癌のバイオマーカー
US20140072969A1 (en) Differential Diagnosis Of Cancer And Other Conditions Based On Expression Of p63
US20060068434A1 (en) Methods and compositions for detecting cancer using components of the U2 spliceosomal particle
US8658376B2 (en) DEK as a urine based biomarker for bladder cancer
Grizzle et al. Factors affecting immunohistochemical evaluation of biomarker expression in neoplasia
Hughes Detection of apoptosis using in situ markers for DNA strand breaks in the failing human heart. Fact or epiphenomenon?
CA1269930A (en) Anticytomegalovirus monoclonal antibodies and processes for the in vitro diagnosis of infections by human cytomegaloviruses and of a protein-kinase inducible by cytomegaloviruses and which can be recognised by the abovesaid monoclonal antibodies
KR20070001913A (ko) 자궁경부 표본에서 암 바이오마커를 검출하기 위한 방법
US20100081192A1 (en) Early prostate cancer antigens (epca), polynucleotide sequences encoding them, and their use
JP7267527B2 (ja) 新規肝癌マーカー
KR101341732B1 (ko) 난소암 진단을 위한 콜라겐 유형 ⅵ 알파 １의 신규한 용도
EP1387173A1 (en) Method for improved diagnosis of cervical lesions based on detection of INK4a gene products
WO2003062828A2 (en) Determining chemotherapeutic effectiveness
CN112180099A (zh) 子宫内膜异位症血清标志物的应用
AU2012326434A1 (en) Predictive biomarkers for breast cancer
JPS62503123A (ja) 免疫複合物の検定のための方法および物品

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060626

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060626

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090831

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100208